Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: A role for the host response in prognosis
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The elucidation of new therapeutic targets of prognostic significance in colon carcinoma is necessary to improve outcomes. In the current study, the authors examined the expression of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) in primary colon carcinoma cases and VEGF in tumor‐associated macrophages (TAM)/stroma, and their correlation with survival. METHODS: The authors identified 131 consecutive American Joint Committee on Cancer Stage II and Stage III colon carcinoma patients seen at the University of Rochester between 1990–1995. Expression of VEGF, EGFR, and CD68 were examined by immunohistochemistry in paraffin‐embedded primary colon tumors and graded as the percentage of cells stained. Data were analyzed using a multivariate Cox proportional hazards model. RESULTS: VEGF expression in tumor was not found to be significantly associated with survival. However, 42% of the patients expressed VEGF in TAM/stroma. The median survival in this group was 9.7 years versus 4.3 years in the VEGF‐negative (TAM/stroma) group (hazards ratio of 0.57, 95% confidence interval [95% CI], 0.34–0.95; P = 0.03). Although TAM infiltration alone was not found to be significant in multivariate analysis, the presence of both CD68 and VEGF (TAM/stroma) was predictive of improved survival (hazards ratio of 0.48, 95% CI, 0.28–0.83; P = 0.006). High grades of EGFR expression (≥ Grade 2) were found to be associated with a trend toward worsened survival. CONCLUSIONS: The greater than twofold increase in median survival associated with VEGF‐expressing TAM suggests a hitherto unknown role for this subset of cells in the host response to colon carcinoma and requires further investigation. Overexpression of EGFR may be associated with worsened survival, providing a rationale for trials of anti‐EGFR agents as adjuvant therapy. Cancer 2003;97:960–8. © 2003 American Cancer Society. DOI 10.1002/cncr.11152
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Vascular endothelial growth factor (VEGF) is an important proangiogenic cytokine and is required to initiate the formation of immature vessels by vasculogenesis or angiogenic sprouting.(4) Tumor cells are the predominant source of VEGF; however, tumor-associated stroma also has been shown to produce VEGF.”
BackgroundBingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022 · cited 2×
“TAM infiltration has been associated with an improved prognosis in patients with carcinoma of the prostate, stomach, and lung, but with a worsened prognosis in patients with breast, cervical, and transitional cell carcinomas.(19) In the current study, the presence of VEGFexpressing TAM was found to be associated signi…”
BackgroundResultInduction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879 · cited 1×
“Angiogenesis is essential for tumor growth and metastasis.(3) Vascular endothelial growth factor (VEGF) is an important proangiogenic cytokine and is required to initiate the formation of immature vessels by vasculogenesis or angiogenic sprouting.”
BackgroundTumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996 · cited 5×
“%) compared with stromal VEGF (42%), implying that a subset of macrophages was expressing VEGF.”
BackgroundInfluentialThe splice variants of vascular endothelial growth factor (VEGF) and their receptors
Robinson, C. J., & Stringer, S. E. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.5.853 · Cited by 944
Interleukin-12: A Cytokine at the Interface of Inflammation and Immunity
Trinchieri, G. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60387-9 · Cited by 760
Vascular endothelial growth factor enhances atherosclerotic plaque progression
Celletti, F. L., Waugh, J. M., Amabile, P. G., Brendolan, A., Hilfiker, P. R., & Dake, M. D. (2001) · Nature Medicine · doi:10.1038/86490 · Cited by 708 · cited 1×
“expressing macrophages recently were demonstrated to further recruit and activate monocytes(29) and to promote plaque progression via an inflammatory process.(30,31) These activities appear to be separate from the well documented proangiogenic role of VEGF in atherosclerosis.”
BackgroundZhao, Q., Egashira, K., Inoue, S., Usui, M., Kitamoto, S., Ni, W., Ishibashi, M., Hiasa, K.-I., Ichiki, T., Shibuya, M., et al. (2002) · Circulation · doi:10.1161/hc0902.104718 · Cited by 136
Cited by
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Zhang, Q.-W., Liu, L., Gong, C.-Y., Shi, H.-S., Zeng, Y.-H., Wang, X.-Z., Zhao, Y.-W., & Wei, Y.-Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050946 · Cited by 1,039
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633
High Macrophage Infiltration along the Tumor Front Correlates with Improved Survival in Colon Cancer
Forssell, J., Öberg, A., Henriksson, M. L., Stenling, R., Jung, A., & Palmqvist, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2073 · Cited by 566
Des Guetz, G., Uzzan, B., Nicolas, P., Cucherat, M., Morere, J.-F., Benamouzig, R., Breau, J.-L., & Perret, G.-Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603176 · Cited by 406
Metadata
- Authors
- Khorana, A. A., Ryan, C. K., Cox, C., Eberly, S., & Sahasrabudhe, D. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-02-03
- Volume
- 97
- Issue
- 4
- Pages
- 960-968
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1518855137
- Cited by
- 152
- References
- 9
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.